Praram 9 Hospital Public Company (PR9) Fair Value & Analysis
Healthcare · TH · Market cap 13.0B THB
Fair value as of: Jun 24, 2026
Analysis
Praram 9 Hospital Public Company (PR9) currently trades at 16.60 THB, while our model-based Fair Value estimate is 22.37 THB — implying the stock looks roughly 34.8% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Praram 9 Hospital Public Company Limited engages in hospital operations primarily in Thailand. The company operates medicine, surgery, diabetes and metabolic, spine, orthopedic, physical therapy and rehabilitation, chest and respiratory, neurology, thyroid and thyroid surgery, obstetrics gynecology, IVF, breast, oncocare, emergency, imaging, Lasik, skin and plastic surgery, mind, gastrointestinal and liver disease, dental, check-up, eye, pediatric, sleep, ear, nose, and throat centers, as well as vaccination and travel medicine, and traditional Chinese medicine clinics. It also engages in the operation of kidney disease and transplantation, cardiovascular, and pain management and wellness institutes. Praram 9 Hospital Public Company Limited was founded in 1992 and is based in Bangkok, Thailand.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Praram 9 Hospital Public Company (PR9) undervalued?
What is the fair value of PR9?
What is the quality score of PR9?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.